Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials. The weight loss pill also significantly improved heart health markers like cholesterol and blood pressure.

In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists developed causes people who are overweight or obese, but not diabetic, to lose significant amounts of weight.

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial saw people lose 12% of body weight.